

14<sup>th</sup> International Symposium on Ocular  
Pharmacology and Therapeutics

# **ISOPT** *Clinical*

March 1-3, 2018 | Tel Aviv, Israel

## **PROGRAM**

Dear colleagues,

It is our great pleasure welcoming you to the 14<sup>th</sup> ISOPT *Clinical* meeting in Tel Aviv, Israel.

This year's meeting will focus on drugs and devices as part of the ophthalmologist tool box dealing with ailments of the eye. Over the last decades a slow, but significant revolution took place with the introduction of new drugs utilizing invasive modes of delivery to the eye. In addition, new devices and drug/device combinations are being launched and change the way we practice ophthalmology today.

The vision of ISOPT *Clinical* had evolved since 1995 centering on:

- Increasing knowledge and awareness of drug utilization in ophthalmology
- Reflecting innovations and their application in daily practice
- Bridging the present to the future

This will be reflected in ISOPT *Clinical* mission:

- Discussion of treatment algorithms in major ophthalmic indications
- Implement data from clinical studies for daily practice
- Facilitate innovation – connecting innovators with clinicians
- Encourage meetings of young innovators with the pharma industry

ISOPT *Clinical* offers a relevant and updated scientific program in a relaxed atmosphere leading to direct interactions of its delegates. We are certain that Interaction with colleagues from many different countries will stimulate a creative exchange of ideas and will be personally rewarding.

We welcome you to Tel Aviv,

**Ron Neumann, MD**

**Sara Krupsky, MD**

ISOPT *Clinical*, Chairs

# COMMITTEES

## Conference Chairs

**Sara Krupsky**, Israel

**Ron Neumann**, Israel

## Special Program Advisor

**Baruch D. Kuppermann**, USA

## Section Chairs:

**Penny A. Asbell**, USA  
Anterior Segment Section

**Ron Neumann**, Israel  
Inflammation Section  
Innovation Section

**Baruch D. Kuppermann**, USA  
Retina Section

**Michal Kremer**, Israel  
Inflammation Section

## Session Chairs:

**Irit Barequet**, Israel  
Infection

**Uday B. Kompella**, USA  
Drug Delivery

**Francine Behar Cohen**, Switzerland  
CNV  
Industry Complexity

**Luis Abegão Pinto**, Portugal  
MIGS

**Eytan Blumenthal**, Israel  
Glaucoma Progression

**Leopold Schmetterer**, Singapore  
Glaucoma Imaging

**Arup Das**, USA  
Therapy of Angiogenesis  
Inhibition DR

**Diane Tang Liu**, USA  
Drug Delivery

**Dan Gatton**, Israel  
Innovations in Ophthalmology by the Tel-Aviv University Team

## INVITED SPEAKERS

**Yonca A. Akova**, Turkey

**Jorge Alio**, Spain

**Florence Allouche Ghrenassia**, France

**Balamurali K. Ambati**, USA

**Aude Ambresin**, Switzerland

**James V. Aquavella**, USA

**Penny A. Asbell**, USA

**Albert J. Augustin**, Germany

**Irit Barequet**, Israel

**Francine Behar-Cohen**, Switzerland

**Michael Belkin**, Israel

**Simon Benita**, Israel

**Paul S. Bernstein**, USA

**Roger W. Beuerman**, Singapore

**Eytan Blumenthal**, Israel

**Francesco Boscia**, Italy

**Elodie Bousquet**, France

**Julia V. Busik**, USA

**Itay Chowers**, Israel

**Maria Francesca Cordeiro**, UK

**Garth Cumberlandidge**, USA

**Arup Das**, USA

**Marc D. de Smet**, The Netherlands

**Diana V. Do**, USA

**Abraham Domb**, Israel

**Yosuf el Shabrawi**, Austria

**Edward Feener**, USA

**Cedric Francois**, USA

**Gerhard Garhöfer**, Austria

**David Goldblum**, USA

**Debra A. Goldstein**, USA

**Michaela Goldstein**, Israel

**Andrzej Grzybowski**, Poland

**Pedram Hamrah**, USA

**Liora Harel**, Israel

**Alon Harris**, USA

**Anton Hommer**, Austria

**Ashwath Jayagopal**, Switzerland

**Choun-Ki Joo**, South Korea

**John H. Kempen**, USA

**Boris Knyazer**, Israel

**Uday B. Kompella**, USA

**Regis P. Kowalski**, USA

**Michal Kramer**, Israel

**Baruch D. Kuppermann**, USA

**Hana Levkovitch Verbin**, Israel

**Phoebe Lin**, USA

**Marco Lupidi**, Italy

## INVITED SPEAKERS (Cont.)

**Irmela Mantel**, Switzerland

**Idit Maya**, Israel

**Dmitry Maychuk**, Russian Federation

**Karl Mercieca**, UK

**Susanne Mohr**, USA

**Elad Moisseiev**, Israel

**Jordi Mones**, Spain

**Raja Narayanan**, India

**Ron Neumann**, Israel

**Quan Dong Nguyen**, USA

**Daniel Palanker**, USA

**John S. Penn**, USA

**Jay S. Pepose**, USA

**Lutz E. Pillunat**, Germany

**Luis Abegão Pinto**, Portugal

**Verena Prokosch-Willing**, Germany

**Jose S. Pulido**, USA

**Eric G. Romanowski**, USA

**Linda Rose**, USA

**Philip J. Rosenfeld**, USA

**Ygal Rotenstreich**, Israel

**Antoine Rousseau**, France

**Ilva D. Rupenthal**, New Zealand

**Leopold Schmetterer**, Singapore

**Robert M. Shanks**, USA

**Shiri Shulman**, Israel

**Debasish Sinha**, USA

**Adrian Smedowski**, Poland

**Abraham Solomon**, Israel

**Diane Tang Liu**, USA

**Joseph Tauber**, USA

**Rolando Toyos**, USA

**Omur Ucakhan Gunduz**, Turkey

**Patricia Udaondo**, Spain

**Arto Urtti**, Finland

**Andy Whitlock**, USA

**Kerstin Wickström**, Sweden

**Clive G. Wilson**, UK

**Manfred Zierhut**, Germany

# Thursday, March 1, 2018

09:00-10:30	<b>MACULAR EDEMA &amp; DIABETIC RETINOPATHY</b> Chair: <b>Michaela Goldstein</b> , Israel	<b>Hall A</b>
09:00	GLYMPHATIC HYPOTHESIS OF DME <b>Francine Behar-Cohen</b> , Switzerland	
09:10	ROLE OF LASER FOR TREATMENT OF DME AND DR IN ANTI-VEGF ERA <b>Francesco Boscia</b> , Italy	
09:20	RESULTS FROM THE 3-YEAR RETRO-IDEAL STUDY: REAL-WORLD ILUVIEN (FLUOCINOLONE ACETONIDE) OUTCOMES AFTER PRIOR TREATMENT <b>Albert J. Augustin</b> , Germany	
09:30	RANDOMIZED, PROSPECTIVE, DOUBLE-MASKED, CONTROLLED PHASE 2B TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ALG-1001 (Luminata®) IN DIABETIC MACULAR EDEMA (DME) <b>Baruch D. Kuppermann</b> , USA	
09:40	THE ROLE OF LASER, ANTI VEGF AND STEROID IN DME - NEW EURETINA GUIDELINES <b>Patricia Udaondo</b> , Spain	
09:50	THE ROLE OF STEROIDS IN DIABETIC MACULAR EDEMA <b>Elad Moisseiev</b> , Israel	
10:00	BIOMARKERS IN DME <b>Patricia Udaondo</b> , Spain	
10:10	COMBINATION THERAPY FOR DME <b>Albert J. Augustin</b> , Germany	
10:20	INTRAVITREAL ANTI-VEGFS FOR TREATMENT OF DR <b>Francesco Boscia</b> , Italy	
09:00-10:30	<b>MOVING FORWARD: A GLIMPSE TO THE FUTURE</b> Chairs: <b>Ron Neumann &amp; Michal Kramer</b> , Israel	<b>Hall B</b>
09:00	GENETIC ANALYSIS IN MULTIFACTORIAL DISEASES: REAL ASSOCIATION VS. EPIPHENOMENA <b>Idit Maya</b> , Israel	
09:15	GENOME WIDE ASSOCIATION STUDY – WILL IT AFFECT THE WAY WE DIAGNOSE/TREAT OCULAR INFLAMMATORY DISEASES? <b>Michal Kramer</b> , Israel	
09:30	THE ROLE OF THE INTESTINAL MICROBIOME IN UNDERSTANDING UVEITIS <b>Phoebe Lin</b> , USA	
09:45	DEVELOPING ALREADY APPROVED DRUGS TO UVEITIS <b>Marc D. de Smet</b> , The Netherlands	

# Thursday, March 1, 2018 (Cont.)

09:00-10:30	<b>MOVING FORWARD: A GLIMPSE TO THE FUTURE (Cont.)</b> Chairs: <b>Ron Neumann &amp; Michal Kramer</b> , Israel	<b>Hall B</b>
10:00	MORBIDITY OF ANTI-INFLAMMATORY THERAPY FOR EYE CONDITIONS <b>John H. Kempen</b> , USA	
10:15	Q & A	
10:30	<i>Coffee, Poster Viewing and Visit the Exhibition</i>	
11:00-12:30	<b>WET AMD &amp; IMAGING</b> Chairs: <b>Albert J. Augustin</b> , Germany & <b>Baruch D. Kuppermann</b> , USA	<b>Hall A</b>
11:00	AMD: THE APPROACH TO DIAGNOSIS AND MANAGEMENT OF PED <b>Michaella Goldstein</b> , Israel	
11:10	COMBINATION IN WET AMD (STEROIDS PLUS X) <b>Albert J. Augustin</b> , Germany	
11:20	AFLIBERCEPT IN WET AMD: FIXED VS PRN REGIMEN <b>Francesco Boscia</b> , Italy	
11:30	OZURDEX AS AN ADJUNCT IN CNVM RESISTANT TO ANTI VEGF <b>Raja Narayanan</b> , India	
11:40	POLYPOIDAL CHOROIDAL VASCULOPATHY <b>Michaella Goldstein</b> , Israel	
11:50	ANGIO OCT AND DME PATIENTS <b>Patricia Udaondo</b> , Spain	
12:00	CASE PRESENTATIONS Moderator: <b>Patricia Udaondo</b> , Spain	
11:00-12:30	<b>INDUSTRY COMPLEXITY</b> Chair: <b>Francine Behar-Cohen</b> , Switzerland	<b>Hall B</b>
11:00	<b>TRANSLATING RESULTS FROM ACADEMIA TO INDUSTRY</b> POINT OF VIEW OF ACADEMIA <b>Francine Behar-Cohen</b> , Switzerland	
11:10	POINT OF VIEW OF COMPANY <b>Andy Whitlock</b> , USA	
11:20	POINT OF VIEW OF COMPANY AND ACADEMIA <b>Ron Neumann</b> , Israel	
11:30	DISCUSSION	

# Thursday, March 1, 2018 (Cont.)

11:00-12:30	<b>INDUSTRY COMPLEXITY (Cont.)</b> Chair: <b>Francine Behar-Cohen</b> , Switzerland	<b>Hall B</b>
<hr/>		
<b>START-UP: MANDATORY STEP?</b>		
11:40	POINT OF VIEW OF STRATEGY-USER <b>Garth Cumberlidge</b> , USA	
11:50	THE ACADEMIA-INDUSTRY INTERFACE CHALLENGE <b>Simon Benita</b> , Israel	
12:00	POINT OF VIEW OF VALORISATION TRANSFER FOR HOSPITAL <b>Florence Allouche Ghrenassia</b> , France	
12:10	DISCUSSION	
<hr/>		
12:30	<i>Lunch, Poster Viewing, and Visit the Exhibition</i>	
<hr/>		
14:00-15:30	<b>DRY AMD &amp; RETINAL DEGENERATION</b> Chairs: <b>Paul S. Bernstein</b> , USA & <b>Jordi Mones</b> , Spain	<b>Hall A</b>
<hr/>		
14:00	GA PHENOTYPES IDENTIFICATION BY CLUSTER ANALYSIS <b>Jordi Mones</b> , Spain	
14:10	FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY (FLIO) OF DRY AMD <b>Paul S. Bernstein</b> , USA	
14:20	CONSENSUS DEFINITION FOR ATROPHY ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION ON OCT (CAM GROUP) <b>Jordi Mones</b> , Spain	
14:30	MACROPHAGES AS A POTENTIAL NOVEL THERAPEUTIC TARGET FOR ATROPHIC AMD <b>Itay Chowers</b> , Israel	
14:40	SAFETY AND ACTIVITY OF A SINGLE, INTRAVITREAL INJECTION OF HUMAN RETINAL PROGENITOR CELLS (JCELL) FOR TREATMENT OF RETINITIS PIGMENTOSA (RP) <b>Baruch D. Kuppermann</b> , USA	
14:50	COMPLEMENT C5 INHIBITION AS A POTENTIAL TREATMENT FOR AUTOSOMAL RECESSIVE STARGARDT DISEASE (STGD1) <b>Elad Moisseiev</b> , Israel	
15:00	PHARMACOGENETICS OF AMD <b>Itay Chowers</b> , Israel	
15:10	CASE PRESENTATIONS <b>Itay Chowers</b> , Israel	



# Thursday, March 1, 2018 (Cont.)

---

14:00-15:30	<b>DRY EYE DISEASE</b> Chairs: <b>Joseph Tauber &amp; Penny A. Asbell, USA</b>	<b>Hall B</b>
14:00	MULTIMODAL OBJECTIVE MARKERS OF DRY EYE DISEASE <b>James V. Aquavella, USA</b>	
14:10	HLADR IN DRY EYE DISEASE <b>Penny A. Asbell, USA</b>	
14:20	PLATELET RICH PLASMA DROPS FOR DRY EYE DISEASE <b>Rolando Toyos, USA</b>	
14:30	SEVERE DRY EYE DISEASE AND TEAR FILM PROTEOMICS IN GVHD <b>David Goldblum, USA</b>	
14:40	RESPONSE TO LIFITEGRAST 5.0% FOR THE TREATMENT OF DRY EYE DISEASE: RESPONDER ANALYSIS FOR REDUCTIONS IN EYE DRYNESS SCORE IN TWO PHASE 3 RANDOMIZED CONTROLLED TRIALS <b>Joseph Tauber, USA</b>	
14:50	Q & A	

---

15:30	<i>Coffee, Poster Viewing and Visit the Exhibition</i>	
-------	--	--

---

---

16:00-17:30	<b>RETINAL VEIN OCCLUSION &amp; CASE DISCUSSIONS</b> Chairs: <b>Raja Narayanan, India &amp; Elad Moisseiev, Israel</b>	<b>Hall A</b>
16:00	MANAGEMENT OF RETINAL VASCULAR OCCLUSIONS <b>Elad Moisseiev, Israel</b>	
16:15	ZALTRAP IN BRVO: EFFICACY AND ECONOMICS <b>Raja Narayanan, India</b>	
16:30	CASE PRESENTATIONS <b>Michaella Goldstein, Israel</b>	
17:10	CAUSATIVE PATHOGENS OF ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI-VEGF INJECTION: AN INTERNATIONAL MULTICENTER STUDY <b>Dinah Zur, Israel</b>	
17:20	DEXAMETHASONE IMPLANT (OZURDEX) FOR DIABETIC MACULAR EDEMA IN NAÏVE COMPARED TO REFRACTORY CASES: A RETROSPECTIVE 24 MONTHS STUDY <b>Matias Iglicki, Argentina</b>	

---

# Thursday, March 1, 2018 (Cont.)

---

16:00-17:30	<b>DRY EYE DISEASE</b> Chairs: <b>Pedram Hamrah &amp; Penny A. Asbell, USA</b>	<b>Hall B</b>
16:00	UPDATES ON TREATMENT OF MGD <b>Pedram Hamrah, USA</b>	
16:10	MG DUCT PROBING, 2017 UPDATE <b>Joseph Tauber, USA</b>	
16:20	TREATING DRY EYE AND MEIBOMIAN GLAND DYSFUNCTION IN THE CONTEMPORARY PRACTICE <b>Linda Rose, USA</b>	
16:30	INTENSE PULSE LIGHT AND LOW-LEVEL LIGHT TREATMENT FOR MGD AND DRY EYE DISEASE <b>Rolando Toyos, USA</b>	
16:40	A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NOVEL MIXTURE OF 0.01% OR 0.02% CYCLOSPORINE A WITH 3% TREHALOSE IN DRY EYE SYNDROME <b>Choun-Ki Joo, South Korea</b>	
16:50	CYCLOSPORINE A IN THE TREATMENT OF PATIENTS WITH SEVERE DRY EYE <b>Ewa Mrukwa Kominek, Poland</b>	
17:00	PANEL - MY APPROACH TO DRY EYE DISEASE / MGD <b>Session Speakers</b>	
17:30	<i>Get-together reception</i>	

---

# Friday, March 2, 2018

08:00-09:00	<b>CNV: CHALLENGING DIAGNOSIS AND TREATMENT</b> Chair: <b>Francine Behar-Cohen</b> , Switzerland	<b>Hall A</b>
08:00	MYOPIC CNV <b>Shiri Shulman</b> , Israel	
08:10	POLYPOIDAL CNV IN CAUCASIAN POPULATION <b>Aude Ambresin</b> , Switzerland	
08:20	CNV COMPLICATING CSCR <b>Irmela Mantel</b> , Switzerland	
08:30	INFLAMMATORY CNV <b>Marco Lupidi</b> , Italy	
08:40	QUIESCENT CNV: SIGNIFICANCE AND MANAGEMENT <b>Elodie Bousquet</b> , France	
08:50	CASE DISCUSSIONS: CHALLENGING CASES <b>Session Speakers</b>	
08:00-09:00	<b>INHIBITION OF DIABETIC RETINOPATHY</b> Chair: <b>Arup Das</b> , USA	<b>Hall B</b>
08:00	ACTIVATION OF LXR AS THERAPEUTIC APPROACH TO NORMALIZE RETINAL CHOLESTEROL METABOLISM IN DIABETIC RETINOPATHY <b>Julia V. Busik</b> , USA	
08:15	TARGETING THE KALLIKREIN-KININ SYSTEMIN DR <b>Edward Feener</b> , USA	
08:30	IL-1B MASTER REGULATOR OF VASCULAR INFLAMMATION IN EARLY DIABETIC RETINOPATHY <b>John S. Penn</b> , USA	
08:45	TARGETING CYTOKINE RECEPTORS TO DISRUPT DEVELOPMENT OF DIABETIC RETINOPATHY <b>Susanne Mohr</b> , USA	
08:00-09:00	<b>PANEL: ANTERIOR SEGMENT DISEASE HOT TOPICS</b> Moderator: <b>Penny A. Asbell</b> , USA	<b>Hall C</b>
	<ul style="list-style-type: none"><li>• INFLAMMATION AS CORE OF DED</li><li>• NEUROPATHIC PAIN</li><li>• SERUM TEARS IN OCULAR SURFACE DISEASE</li><li>• STEROIDS IN CORNEAL ULCERS</li><li>• CXL FOR INFECTIONS</li></ul>	
	Discussants: <b>James V. Aquavella</b> , USA <b>Pedram Hamrah</b> , USA <b>Jay S. Pepose</b> , USA <b>Linda Rose</b> , USA <b>Omur Ucakhan Gunduz</b> , Turkey	

# Friday, March 2, 2018 (Cont.)

---

09:00-11:00 **INNOVATIONS IN OPHTHALMOLOGY BY THE TEL-AVIV UNIVERSITY TEAM** **Hall A**

Chair: **Dan Gaton**, Israel



Department of Ophthalmology  
Sackler Faculty of Medicine  
Tel Aviv University

החוג לרפואת עיניים  
הפקולטה לרפואה ע"ש סאקלר  
אוניברסיטת תל אביב

---

**OPENING REMARKS**

09:00 **Dan Gaton**, Israel

09:05 **Ehud Grossman**, Israel

09:15 HISTORY OF THE DEPARTMENT OF OPHTHALMOLOGY IN VIEW OF THE TEL-AVIV UNIVERSITY

**Dan Gaton**, Israel

09:30 BIG DATA AND ARTIFICIAL INTELLIGENCE IN RETINAL DISEASES

**Anat Loewenstein**, Israel

09:45 A JOURNEY INTO THE THIRD MILLENIUM...

**Joseph Moisseiev**, Israel

10:00 CORNEAL TRANSPLANTS - SCIENCE FICTION OR REALITY?

**Irit Bahar**, Israel

10:15 THINKING OUT OF THE BOX – ORIGINAL DEVELOPMENTS IN OPHTHALMOLOGY

**Ehud Assia**, Israel

10:30 CATARACT IN SMALL INCISION - SMILE OR FROWN

**Elisha Bartov**, Israel

10:45 THE IMPLICATIONS OF GENE SEQUENCING IN OPHTHALMOLOGY

**Eran Pras**, Israel

---

09:00-09:45 **MIGS - WHEN, WHO AND WHY?** **Hall B**

Chair: **Luis Abegão Pinto**, Portugal

09:00 THRESHOLD FOR MIGS SURGERY

**Antoine Rousseau**, France

09:10 CHOOSING YOUR MIGS: STAND ALONE PROCEDURE

**Verena Prokosch-Willing**, Germany

# Friday, March 2, 2018 (Cont.)

09:00-09:45	<b>MIGS - WHEN, WHO AND WHY? (Cont.)</b> Chair: <b>Luis Abegão Pinto</b> , Portugal	<b>Hall B</b>
09:20	CHOOSING YOUR MIGS: COMBINED SURGERY <b>Karl Mercieca</b> , UK	
09:30	PLACING MIGS IN YOUR TREATMENT ALGORITHM <b>Luis Abegão Pinto</b> , Portugal	
09:40	Q & A	
09:00-09:45	<b>PANEL: RETINA HOT TOPICS</b> Moderator: <b>Baruch D. Kuppermann</b> , USA	<b>Hall C</b>
	<ul style="list-style-type: none"> <li>•ANTI VEGF               <ul style="list-style-type: none"> <li>•THE FATE OF ANTI VEGF IN THE FUTURE</li> <li>•BETTER DELIVERY SYSTEMS?</li> <li>•HAVE WE REACHED MOST IN EFFICACY TERMS OF THE CURRENT TECHNOLOGIES?</li> <li>•THE TIME FOR COMBINATION THERAPIES - THE POST FOVISTA ERA                   <ul style="list-style-type: none"> <li>•STEROIDS AND ANTI VEGF FOR DME?</li> </ul> </li> </ul> </li> <li>•DRY AMD               <ul style="list-style-type: none"> <li>•WHY IS IT SO DIFFICULT TO DEMONSTRATE EFFICACY?</li> <li>•THE CHALLENGE OF ENDPOINTS FOR THE INDICATION – BEYOND MICROPERIMETRY</li> </ul> </li> </ul> <p>Discussants:  <b>Paul S. Bernstein</b>, USA  <b>Diana V. Do</b>, USA  <b>Jordi Mones</b>, Spain  <b>Philip J. Rosenfeld</b>, USA</p>	
09:45-10:30	<b>NEW CONCEPTS IN GLAUCOMA</b> Chair: <b>Eytan Blumenthal</b> , Israel	<b>Hall B</b>
09:45	GLAUCOMA: A COMPLEX INTERACTION BETWEEN IOP, BP, PP, CSFP AND BLOOD FLOW <b>Alon Harris</b> , USA	
09:55	OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY – DOES IT HAVE VALUE IN GLAUCOMA? <b>Leopold Schmetterer</b> , Singapore	
10:05	THE HURDLES ON THE WAY FROM SCIENCE TO THE PATIENT <b>Anton Hommer</b> , Austria	
10:15	NEW OCULAR BIOMARKERS IN GLAUCOMA AND NEURODEGENERATION <b>Maria Francesca Cordeiro</b> , UK	
10:25	Q & A	

# Friday, March 2, 2018 (Cont.)

09:45-10:30	<b>PANEL: UVEITIS HOT TOPICS</b> Moderator: <b>Ron Neumann</b> , Israel	<b>Hall C</b>
	<ul style="list-style-type: none"><li>• THE NEED FOR QUANTITATIVE MEASUREMENT IN OUR PRACTICES</li><li>• THE FLARE/CELLS CONUNDRUM</li><li>• THE INTERDISCIPLINARY CLINIC FOR INFLAMMATORY PATIENTS: A DREAM OR REALITY?</li><li>• LOOKING FOR THE NEXT UVEITIS DRUG: PRECLINICAL DATA? RHEUMATOLOGICAL DATA? REPURPOSING OLD DRUGS? WHAT WOULD BE THE BEST PREDICTORS?</li></ul> <p>Discussants: <b>Michal Kramer</b>, Israel <b>Quan Dong Nguyen</b>, USA <b>Marc D. de Smet</b>, The Netherlands <b>Manfred Zierhut</b>, Germany</p>	
10:30	<i>Coffee, Poster Viewing and Visit the Exhibition</i>	
11:00-12:00	<b>NON INFECTIOUS UVEITIS</b> Chair: <b>Michal Kramer</b> , Israel	<b>Hall A</b>
11:00	PHARMACOTHERAPY IN DEVELOPMENT FOR NON-INFECTIOUS POSTERIOR UVEITIS: WHAT CAN WE EXPECT FROM CLINICAL TRIALS? <b>Quan Dong Nguyen</b> , USA	
11:15	THE ROLE OF TNF INHIBITOR ANTIBODIES IN THE RHEUMATOLOGIST SCHEME OF THERAPY <b>Liora Harel</b> , Israel	
11:30	ATTENUATION OF INTRAOCULAR INFLAMMATORY RESPONSES IN EXPERIMENTAL AUTOIMMUNE UVEITIS BY TMP IS ASSOCIATED WITH MODULATING OF THE STAT3 AND STAT4 PATHWAYS <b>Bo Lei</b> , China	
11:40	Q & A	
11:00-12:30	<b>GLAUCOMA IMAGING</b> Chairs: <b>Leopold Schmetterer</b> , Singapore & <b>Gerhard Garhöfer</b> , Austria	<b>Hall B</b>
11:00	GLAUCOMA IMAGING IN CURRENT PRAXIS <b>Anton Hommer</b> , Austria	
11:15	DETECTION OF APOPTOSING RETINAL CELLS <b>Maria Francesca Cordeiro</b> , UK	

# Friday, March 2, 2018 (Cont.)

---

11:00-12:30	<b>GLAUCOMA IMAGING (Cont.)</b> Chair: <b>Leopold Schmetterer</b> , Singapore & <b>Gerhard Garhöfer</b> , Austria	<b>Hall B</b>
11:30	FUTURE OF IMAGING - MULTIMODALITY AND DEEP LEARNING <b>Leopold Schmetterer</b> , Singapore	
11:45	IMAGING ENDPOINTS IN CLINICAL TRIALS <b>Gerhard Garhöfer</b> , Austria	
12:00	INTRAOCULAR PRESSURE REDUCTION BY DIGOXIN DERIVATIVES THAT SELECTIVELY INHIBIT NA,K-ATPASE OF THE NON PIGMENTED EPITHELIUM OF THE CILIARY BODY <b>Arie Marcovich</b> , Israel	
12:09	OBJECTIVE DIAGNOSIS AND ASSESSMENT OF VISUAL FIELD DEFECTS IN GLAUCOMA PATIENTS USING CHROMATIC MULTIFOCAL PUPILLOMETRY <b>Ifat Sher</b> , Israel	
12:16	OPTIC NEURITIS MONITORING USING OBJECTIVE AND SUBJECTIVE VISUAL FIELD TESTING <b>Zachary Weinerman</b> , Israel	
12:23	OBJECTIVE PERIMETRY IN PATIENTS WITH RETINITIS PIGMENTOSA USING CHROMATIC PUPILLOPERIMETRY <b>Ygal Rotenstreich</b> , Israel	
11:00-11:45	<b>PANEL: DRUG DELIVERY HOT TOPICS</b> Moderators: <b>Uday B. Kompella</b> & <b>Diane Tang Liu</b> , USA	<b>Hall C</b>
	<ul style="list-style-type: none"><li>• TOPICAL NANOSPHERES FOR BACK OF THE EYE DRUG DELIVERY</li><li>• STIMULI-RESPONSIVE DRUG DELIVERY SYSTEMS</li><li>• DRUG BINDING TO VITREOUS HUMOR AND IMPLICATIONS FOR DELIVERY</li><li>• DELIVERY FOR THE AGEING EYE</li></ul> Discussants: <b>Abraham Domb</b> , Israel <b>Ashwath Jayagopal</b> , Switzerland <b>Arto Urtti</b> , Finland <b>Clive G. Wilson</b> , UK	

---

# Friday, March 2, 2018 (Cont.)

---

11:45-12:30	<b>PANEL: GLAUCOMA HOT TOPICS</b> Moderator: <b>Eytan Blumenthal</b> , Israel	<b>Hall C</b>
-------------	--	---------------

---

- THE MEDICAL TREATMENT OF GLAUCOMA 5 AND 15 YEARS FROM NOW. NEW COMPOUNDS, DELIVERY METHODS, DISAPPEARANCE OF CURRENT OPTIONS, REVOLUTIONS?  
The optimistic opinion:  
**Maria Francesca Cordeiro**, UK  
The pessimistic opinion:  
**Leopold Schmetterer**, Singapore
- WILL “PERSONALIZED MEDICINE” BE COMMONLY USED IN GLAUCOMA 5 YEARS FROM NOW? IF SO, WHAT AND HOW?  
The optimistic opinion:  
**Hana Levkovitch Verbin**, Israel  
The pessimistic opinion:  
**Alon Harris**, USA

---

12:30-14:00	<b>COMPANY SPONSORED LUNCH SESSION</b>	
-------------	--	--

---

14:00-15:30	<b>DRY AMD AND IMAGING</b> Chair: <b>Diana V. Do &amp; Cedric Francois</b> , USA	<b>Hall A</b>
-------------	---	---------------

---

14:00	APL-2, A COMPLEMENT C3 INHIBITOR, SLOWS THE GROWTH OF GEOGRAPHIC ATROPHY SECONDARY TO AMD: 12-MONTH RESULTS OF A PHASE 2 CLINICAL TRIAL (FILLY) <b>Cedric Francois</b> , USA	
14:15	INCREASED EXUDATION AFTER C3 INHIBITION: IS SS-OCTA NECESSARY FOR NON-EXUDATIVE AMD CLINICAL TRIALS? <b>Philip J. Rosenfeld</b> , USA	
14:30	RPE CELL TRANSPLANTATION FOR GEOGRAPHIC ATROPHY <b>Diana V. Do</b> , USA	
14:45	SS-OCT ANGIOGRAPHIC IMAGING OF THE CHORIOCAPILLARIS <b>Philip J. Rosenfeld</b> , USA	
15:00	SS-OCT ANGIOGRAPHIC IMAGING OF NON-EXUDATIVE AND EXUDATIVE AMD <b>Philip J. Rosenfeld</b> , USA	
15:15	POTENTIAL ROLE OF MICROPERIMETRY IN THE ASSESSMENT OF GEOGRAPHIC ATROPHY <b>Quan Dong Nguyen</b> , USA	

---



# Friday, March 2, 2018 (Cont.)

---

14:00-15:30	<b>INNOVATION</b>	<b>Hall B</b>
	Chairs: <b>Ron Neumann &amp; Ygal Rotenstreich</b> , Israel	
14:00	NOVALIQ <b>Gabriela Burian</b> , Germany	
14:15	OPTCEUTICS <b>Barry Butler</b> , USA	
14:30	BIOLIGHT <b>Suzana Nahum Zilberberg</b> , Israel	
14:45	EYEVENSIS <b>Ron Neumann</b> , Switzerland	
15:00	PANOPTES PHARMA <b>Franz Obermayr</b> , Austria	
15:15	CELL CURE <b>Diana V. Do</b> , USA	
14:00-15:30	<b>DRUG DELIVERY</b>	<b>Hall C</b>
	Chairs: <b>Uday B. Kompella &amp; Diane Tang Liu</b> , USA	
14:00	NON-INVASIVE IONTOPHORTIC DELIVERY OF DRUGS TO THE EYE <b>Abraham Domb</b> , Israel	
14:15	MELANIN BINDING AND TRANSPORT PROCESSES IN RETINAL PHARMACOKINETICS <b>Arto Urtti</b> , Finland	
14:30	OVERCOMING BIOLOGICAL BARRIERS TO ENHANCE OCULAR DRUG DELIVERY <b>Ilva D. Rupenthal</b> , New Zealand	
14:45	LOWERING THE PRESSURE – A ROUTE TO ACCESS THE INNER EYE <b>Clive G. Wilson</b> , UK	
15:00	DEVELOPMENT AND MODELING OF PROTEIN-BASED DRUG DELIVERY SYSTEMS <b>Ashwath Jayagopal</b> , Switzerland	
15:15	NOVEL DRUG DELIVERY IN OPHTHALMOLOGY <b>Ishay Attar</b> , Israel	
15:30	<i>Coffee, Poster Viewing and Visit the Exhibition</i>	

---

# Friday, March 2, 2018 (Cont.)

---

16:00-17:30	<b>CORNEA DEVICES / INNOVATION</b>	<b>Hall A</b>
	Chairs: <b>Jay S. Pepose &amp; Penny A. Asbell, USA</b>	
16:00	STANDARD VS ACCELERATED (9 mW/cm <sup>2</sup> ) CORNEAL COLLAGEN CXL: 2-YEAR OUTCOMES <b>Omur Ucakhan Gunduz, Turkey</b>	
16:10	CXL FOR RECURRENT KERATOCONUS IN EYES AFTER PENETRATING KERATOPLASTY <b>Irit Barequet, Israel</b>	
16:20	AN UPDATE ON CONTACT LENSES AND MYOPIA CONTROL <b>Omur Ucakhan Gunduz, Turkey</b>	
16:30	THE ANTERIOR CHAMBER OF THE EYE AS A CLINICAL TRANSPLANTATION SITE OF PANCREATIC ISLETS FOR THE TREATMENT OF DIABETES: A STUDY IN A RAT MODEL OF DIABETES <b>Choun-Ki Joo, South Korea</b>	
16:40	PANCREATIC INSLET TRANSPLANTATION INTO THE ANTERIOR CHAMBER; FIRST IN MAN <b>David Goldblum, USA</b>	
16:50	EFFECT OF LIFITEGRAST THERAPY ON SIGNS AND SYMPTOMS IN DRY EYE DISASE <b>Jay S. Pepose, USA</b>	
17:00	THE HYPER-CL™ MULTI-CENTER STUDY <b>Ofer Daphna, Israel</b>	
17:10	SAFETY OF CORNEAL CROSS-LINKING IN THIN CORNEAS: COMPARING LIGHT ATTENUATION IN RIBOFLAVIN /ULTRA-VIOLET A VERSUS LIMITED PHOTSENSITIZER PENETRATION WST-D/NEAR INFRA-RED PROTECTING THE ENDOTHELIUM IN CORNEAS BELOW 400µM <b>Arie Marcovich, Israel</b>	
17:20	Q & A	

---

# Friday, March 2, 2018 (Cont.)

---

16:00-17:00	<b>INNOVATION</b> Chairs: <b>Ron Neumann &amp; Ygal Rotenstreich</b> , Israel	<b>Hall B</b>
16:00	OPHTHALMIC DEVICES: TWISTED JOURNEYS FROM IDEAS TO PRODUCTS <b>Daniel Palanker</b> , USA	
16:15	FABULOUS FAILURES IN OPTHALMIC TECHNOLOGY DEVELOPMENT <b>Michael Belkin</b> , Israel	
16:30	REQUIREMENTS ON BIOMARKERS AND SURROGATE ENDPOINTS IN THE DEVELOPMENT OF DRUGS FOR OCULAR DISEASE. A EUROPEAN REGULATORY VIEW <b>Kerstin Wickström</b> , Sweden	
16:45	COMPUTERIZING THE VISUAL ACUITY TEST <b>Eytan Blumenthal</b> , Israel	
17:00-17:45	<b>PANEL: DRUG DEVELOPMENT HOT TOPICS</b> Moderator: <b>Ron Neumann</b> , Israel	<b>Hall B</b>
	<ul style="list-style-type: none"><li>•DEVELOPMENT OF NEW OPTHALMIC PRODUCTS<ul style="list-style-type: none"><li>•THE INTERPLAY BETWEEN BIG PHARMA AND STARTUPS</li><li>•MAJOR UNMET NEEDS.</li></ul></li><li>•WHEN DEVELOPMENT FAILS:<ul style="list-style-type: none"><li>•RESPONSIBILITY FOR ASSESSING FAILING STUDIES</li><li>•OBLIGATION TO PUBLISH<ul style="list-style-type: none"><li>• INVESTIGATORS? SPONSORS?</li></ul></li></ul></li></ul>	
	Discussants: <b>Barry Butler</b> , USA <b>Michael Belkin</b> , Israel <b>Daniel Palanker</b> , USA <b>Kerstin Wickström</b> , Sweden	

---

# Friday, March 2, 2018 (Cont.)

---

16:00-17:30	<b>DRUG DELIVERY</b> Chairs: <b>Uday B. Kompella &amp; Diane Tang Liu, USA</b>	<b>Hall C</b>
16:00	PROLONGING DRUG RESIDENCE IN VITREOUS HUMOR: BIOPHARMACEUTICAL CONSIDERATIONS <b>Diane Tang Liu, USA</b>	
16:15	BIODEGRADABLE IMPLANTS FOR SUSTAINED DRUG RELEASE: MANUFACTURING CONSIDERATIONS, DRUG STABILITY, AND DRUG RELEASE <b>Uday B. Kompella, USA</b>	
16:30	LENS CAPSULE SUSTAINED DELIVERY SYSTEM FOR DEXAMETHASONE <b>Balamurali K. Ambati, USA</b>	
16:45	DRUG-DEVICE COMBINATION APPROACHES FOR DELIVERY TO THE EYE <b>Ilva D. Rupenthal, New Zealand</b>	
17:00	CHALLENGES IN TRANSLATING PRECLINICAL STUDIES TO CLINICAL SUCCESS <b>Andy Whitlock, USA</b>	
17:15	TECHNOLOGIES OF SOLUBILIZING OF LIPOPHILIC PROSTAGLANDIN ANALOGUES FOR TOPICAL DELIVERY <b>Adrian Smedowski, Poland</b>	
17:45	<i>End of Day's Sessions</i>	

---

# Saturday, March 3, 2018

---

08:00-09:00	<b>TNF INHIBITORS / INTRAOCULAR LYMPHOMA</b> Chairs: <b>Manfred Zierhut</b> , Germany & <b>Marc D. de Smet</b> , The Netherlands	<b>Hall A</b>
08:00	DEFINING FAILURE OF TNF INHIBITORS <b>Manfred Zierhut</b> , Germany	
08:20	UVEITIS INDUCED BY BIOLOGIC AGENTS USED IN CANCER THERAPY <b>Iris Deitch</b> , Israel	
08:30	NEW DIAGNOSTIC TOOLS FOR VITREO-RETINAL LYMPHOMA <b>Jose S. Pulido</b> , USA	
08:50	DISCUSSION <b>Session Speakers</b>	
08:00-09:00	<b>THERAPY OF ANGIOGENESIS</b> Chair: <b>Arup Das</b> , USA	<b>Hall B</b>
08:00	GEFITINIB AS A NOVEL THERAPY FOR PERSISTENT FETAL VASCULAR DISEASE <b>Debasish Sinha</b> , USA	
08:15	EMERGING DIAGNOSTIC STRATEGIES FOR DR <b>Ashwath Jayagopal</b> , Switzerland	
08:30	DRGen STUDY: NOVEL GENETIC VARIANTS IN EXTREME AND ADVANCED PHENOTYPES OF DIABETIC RETINOPATHY <b>Arup Das</b> , USA	
08:45	EMERGING DRUG DELIVERY STRATEGIES FOR DR <b>Ashwath Jayagopal</b> , Switzerland	
09:00-10:30	<b>WOUND HEALING / INFECTIONS</b> Chairs: <b>James V. Aquavella</b> & <b>Penny A. Asbell</b> , USA	<b>Hall A</b>
09:00	NEW MEAN OF AUTOLOGOUS CELLS FOR PERSISTENT CORNEAL ULCERS <b>Jorge Alio</b> , Spain	
09:10	THE ROLE OF BIOFILM IN CORNEAL INFECTIONS <b>Roger W. Beuerman</b> , Singapore	
09:20	BOTOX TARSORRHAPHY AND PROKERA RINGS IN THE TREATMENT OF CORNEAL ULCERS <b>Linda Rose</b> , USA	
09:30	TOPICAL ANTIMICROBIAL PROPHYLAXIS <b>James V. Aquavella</b> , USA	

---

# Saturday, March 3, 2018 (Cont.)

09:00-10:30	<b>WOUND HEALING/ INFECTIONS (Cont.)</b> Chairs: <b>James V. Aquavella &amp; Penny A. Asbell, USA</b>	<b>Hall A</b>
09:40	COSMETIC, RECURRENCE-FREE PTERYGIUM SURGERY: SIMPLIFYING THE P.E.R.F.E.C.T. TECHNIQUE WITH AMNIOTIC MEMBRANE <b>Linda Rose, USA</b>	
09:50	MANAGEMENT OF NEUROPATHIC CORNEAL PAIN <b>Pedram Hamrah, USA</b>	
10:00	Q & A	
09:00-10:30	<b>OCULAR BLOOD FLOW IN GLAUCOMA</b> Chair: <b>Lutz E. Pillunat, Germany</b>	<b>Hall B</b>
09:00	THE EFFECTS OF ANTIOXIDANTS ON OCULAR BLOOD FLOW IN PATIENTS WITH GLAUCOMA <b>Alon Harris, USA</b>	
09:15	RETINAL OXYGEN EXTRACTION IN GLAUCOMA <b>Leopold Schmetterer, Singapore</b>	
09:30	CENTRAL RETINAL VENOUS PRESSURE IN GLAUCOMA PATIENTS <b>Lutz E. Pillunat, Germany</b> <b>GLAUCOMA FREE PAPERS</b> Chair: <b>Lutz E. Pillunat, Germany</b>	
09:45	EFFECT OF ORALLY ADMINISTERED NITRATES ON CENTRAL RETINAL VENOUS PRESSURE IN PRIMARY OPEN ANGLE GLAUCOMA PATIENTS <b>Karin Roswitha Pillunat, Germany</b>	
09:55	THE EFFECT OF SILDENAFIL ON RETINAL BLOOD VELOCITY IN HEALTHY SUBJECTS <b>Asaf Achiron, Israel</b>	
10:05	EVALUATION OF TRABECULAR MICRO-BYPASS STENTS IN COMBINATION WITH CATARACT SURGERY: OUTCOMES FROM A LARGE COHORT OF A SINGLE-SURGEON <b>Eva I. Liang, USA</b>	
10:15	EFFECTS OF LIFESTYLE CHANGES ON INTRA-OCULAR PRESSURE AND ILLNESS PERCEPTION IN PATIENTS WITH GLAUCOMA – A RANDOMIZED CONTROLLED TRIAL <b>Asaf Achiron, Israel</b>	
10:25	Q & A	
10:30	<i>Coffee, Poster Viewing and Visit the Exhibition</i>	

# Saturday, March 3, 2018 (Cont.)

11:00-12:30	<b>WOUND HEALING / INFECTIONS</b> Chairs: <b>Omur Ucakhan Gunduz</b> , Turkey & <b>Penny A. Asbell</b> , USA	<b>Hall A</b>
11:00	DIAGNOSIS AND TREATMENT OF NEUROTROPHIC KERATOPATHY <b>Pedram Hamrah</b> , USA	
11:10	A NEW RAPID, NON-INVASIVE, METHOD FOR IDENTIFYING THE PATHOGEN IN A CORNEAL INFECTION <b>Roger W. Beuerman</b> , Singapore	
11:20	CXL FOR CORNEAL INFECTIONS <b>Penny A. Asbell</b> , USA	
11:30	EndoArt & AMP; HYPER CL - INITIAL RESULTS IN HUMAN SUFFERING FROM CORNEAL EDEMA <b>Nahum Ferera</b> , Israel	
11:40	PANEL - CONTROVERSIES IN TREATING CORNEAL INFECTIONS Moderator: <b>Irit Barequet</b> , Israel Discussants: <b>Penny A. Asbell</b> , USA <b>Roger W. Beuerman</b> , Singapore <b>Nahum Ferera</b> , Israel <b>Pedram Hamrah</b> , USA <b>Omur Ucakhan Gunduz</b> , Turkey	
11:00-12:30	<b>RETINA FREE PAPERS</b> Chair: <b>Arieh S. Solomon</b> , Israel	<b>Hall B</b>
11:00	COMPARING CHOROIDAL THICKNESS MEASUREMENTS ON SWEEP SOURCE AND SPECTRAL DOMAIN COHERENCE TOMOGRAPHY <b>Colin Siang Hui Tan</b> , Singapore	
11:10	NANO-DROPS FOR CORRECTING THE REFRACTIVE ERRORS <b>David Smadja</b> , Israel	
11:20	A COMPARISON OF VARIOUS EQUATIONS IN THE PREDICTION OF RETINAL THICKNESS ON OPTICAL COHERENCE TOMOGRAPHY <b>Colin Siang Hui Tan</b> , Singapore	
11:30	A NOVEL TECHNIQUE TO EVALUATE RETINAL VASCULAR DENSITY ON OCT <b>Kelvin Li</b> , Singapore	
11:40	PROLONGED INHIBITION OF SEMAPHORINA PATHWAY VIA BIODEGRADABLE IMPLANT TOWARDS A BETTER THERAPY FOR VISUAL SENSORY IMPAIRMENTS <b>Arieh S. Solomon</b> , Israel	
11:50	ACUTE ALCOHOLISM-INDUCED RPE DAMAGE AND CHOROIDAL THICKENING: A CASE REPORT <b>Xiaoling Liu</b> , China	

# Saturday, March 3, 2018 (Cont.)

---

11:00-12:30	<b>RETINA FREE PAPERS (Cont.)</b> Chair: <b>Arieh S. Solomon</b> , Israel	<b>Hall B</b>
12:00	PROTECTION OF RETINAL CELLS THROUGH HYPOTHERMIA TREATMENT <b>Stephanie C. Joachim</b> , Germany	
12:10	SIX YEARS AND COUNTING! LONG TERM RESTORATION OF PHOTOPIC RETINAL FUNCTION AND VISUAL BEHAVIOR FOLLOWING GENE THERAPY IN A SHEEP MODEL OF CNGA3 ACHROMATOPSIA <b>Ron Ofri</b> , Israel	
12:20	REDUCTION OF POST INTRAVITREAL INJECTION PAIN USING ICE: AN OPEN-LABEL INTERVENTIONAL RANDOMIZED TRIAL <b>Asaf Achiron</b> , Israel	
<hr/>		
12:30	<i>Lunch, Poster Viewing, and Visit the Exhibition</i>	
<hr/>		

---

14:00-15:30	<b>IMMUNOSUPPRESSION IS NOT THE WHOLE STORY</b> Chairs: <b>Ron Neumann &amp; Michal Kramer</b> , Israel	<b>Hall A</b>
14:00	PERIOPERATIVE TREATMENT IN UVEITIC CATARACT PATIENTS <b>Yosuf el Shabrawi</b> , Austria	
14:15	EFFECT OF INTRAVITREAL SIROLIMUS ON VITREOUS HAZE AND CENTRAL RETINAL THICKNESS: RESULTS OF THE SAKURA PROGRAM <b>Debra A. Goldstein</b> , USA	
14:30	CMV UVEITIS DIAGNOSTIC AND THERAPEUTIC CONSIDERATIONS <b>Yonca A. Akova</b> , Turkey	
14:45	IOL SUBLUXATION IN CHRONIC UVEITIS <b>Shiri Shulman</b> , Israel	
15:00	THE ROLE OF IPSC-RPE IN VIVO AND IN VITRO <b>Jose S. Pulido</b> , USA	
15:20	DISCUSSION <b>Session Speakers</b>	



# Saturday, March 3, 2018 (Cont.)

---

14:00-15:30	<b>RETINA FREE PAPERS</b> Chair: <b>Arieh S. Solomon</b> , Israel	<b>Hall B</b>
14:00	IRON TOXICITY CONTRIBUTES TO FUNCTIONAL LOSS IN SUCCESSFUL RHEGMATOGENOUS RETINAL DETACHMENTS <b>Emilie Picard</b> , France	
14:10	SCLERAFIXATED FLUOCINOLONACETONID IMPLANT FOR CME IN APHACIC OR SEVERLY DAMAGED EYES <b>Armin Wolf</b> , Germany	
14:20	CMV SPECIFIC T LYMPHOCYTE INFUSION: A NOVEL TREATMENT FOR RESISTANT CMV RETINITIS <b>Tal Saban</b> , Israel	
14:30	DEMONSTRATION OF A NOVEL PHASE IMAGING METHOD TO VISUALIZE RETINAL CELLS <b>Laura Kowalczyk</b> , Switzerland	
14:40	GENE THERAPY STRATEGIES FOR HYPOXIA-INDUCIBLE ANGIOGENESIS IN OCULAR NEOVASCULARIZATION <b>Helder Andre</b> , Sweden	
14:50	MINIATURE INTRAOCULAR IMPLANT DESIGNED FOR LONG-ACTING RELEASE (LAR) OF ANTI-VEGF THERAPY <b>Szilard Kiss</b> , USA	
15:00	UPARANT IS AN EFFECTIVE ANTIANGIOGENIC IN A MOUSE MODEL OF RUBEOSIS IRIDIS <b>Helder Andre</b> , Sweden	
15:10	OCTA IN MAC TEL – NEW AND COMPLIMENTARY MULTI-MODAL IMAGING FINDINGS <b>Ethan Priel</b> , Israel	
15:20	DIFFUSE DIABETIC MACULAR EDEMA: THE PATHOGENESIS LINE HAS BEEN DISCLOSED <b>Avinoam Ophir</b> , Israel	
15:30	<i>Coffee, Poster Viewing and Visit the Exhibition</i>	

---

# Saturday, March 3, 2018 (Cont.)

---

16:00-17:40	<b>INFECTIONS</b> Chair: <b>Irit Barequet</b> , Israel	<b>Hall A</b>
16:00	ANTIBIOTICS RESISTANCE IN OPHTHALMOLOGY: UPDATE 2018 <b>Andrzej Grzybowski</b> , Poland	
16:10	SURVEILLANCE STUDIES ON INTRAOCULAR SAMPLE <b>Penny A. Asbell</b> , USA	
16:20	ANTISEPTICS VS ANTIBIOTICS IN OPHTHALMOLOGY <b>Andrzej Grzybowski</b> , Poland	
16:30	THE IN VITRO EVALUATION OF THE MICROBICIDAL ACTIVITY OF VBP-100, A PROPRIETARY GEL FORMULATION OF 0.25% POVIDONE-IODINE <b>Eric G. Romanowski</b> , USA	
16:40	ACANTHAMOEBA KERATITIS - DIAGNOSTIC AND TERAPEUTIC CHALLENGES <b>Abraham Solomon</b> , Israel	
16:50	TOPICAL PENICILLIN TREATMENT OF STAPYLOCOCCUS AUREUS WITH ELEVATED MICS TO PENICILLIN IN A RABBIT KERATITIS MODEL <b>Regis P. Kowalski</b> , USA	
17:00	PACK-CXL (PHOTOACTIVATED CHROMOPHORE FOR KERATITIS-CORNEAL COLLAGEN CROSS-LINKING) AS TREATMENT FOR INFECTIONS KERATITIS <b>Boris Knyazer</b> , Israel	
17:10	THE USE OF PREDATORY BACTERIA TO CONTROL HUMAN OCULAR PATHOGENS <b>Robert M. Shanks</b> , USA	
17:20	OKG-0301, A NOVEL RIBONUCLEASE, DEMONSTRATES ANTIVIRAL ACTIVITY AGAINST ADENOVIRUS IN THE AD5/NZW RABBIT OCULAR MODEL <b>Eric G. Romanowski</b> , USA	
17:30	RECURRENCE OF INFILTRATES AFTER ADENOVIRAL KERATITIS <b>Dmitry Maychuk</b> , Russian Federation	
17:40	<i>End of Day's Sessions</i>	

---

# **POSTER PRESENTATIONS**

## POSTER PRESENTATIONS

1. MULTIMODAL IMAGING OF CHOROIDAL AND OPTIC DISC VESSELS NEAR OPTIC DISC PITS  
**Matthew K. Adams**, USA
2. EFFICIENCY OF THERAPY OF MACULAR EDEMA ASSOCIATED WITH NON-INFECTIOUS UVEITIS  
**Liubov Danilova**, Russian Federation
3. COMPUTATIONAL MODELLING TO GIVE NEW INSIGHTS IN THE FIELD OF OCULAR MELANIN BINDING  
**Eva Maria Del Amo**, Finland
4. IOP VARIATION WITH SUBCONJUNCTIVAL ACETAZOLAMIDE DDS ON NZW RABBITS  
**Manuel N. Gaspar**, Portugal
5. ANATOMIC AND FUNCTIONAL RESULTS AFTER SWITCHING TO AFLIBERCEPT IN POOR RESPONDERS TO RANIBIZUMAB IN NEOVASCULAR AMD  
**Maria Isabel López Gálvez**, Spain
6. STUDY OF THE REGULATION OF THE RECOVERY PROCESSES AT METABOLIC LEVEL IN THE TISSUES OF ANTERIOR SURFACE OF THE EYE IN CONDITIONS OF HYPOXIA  
**Yuliya Markitantova**, Russian Federation
7. MANAGEMENT OF LATE CYSTOID MACULAR OEDEMA IN ACUTE RETINAL NECROSIS SECONDARY TO HERPES ZOSTER VIRUS WITH INTRAVITREAL TRIAMCINOLONE  
**Victor Menezo**, Spain
8. INNOVATIVE EYE DROPS CONTAINING SEMIFLUORINATED ALKANES FOR THE TREATMENT OF DRY EYE SYNDROME  
**Ewa Mrukwa Kominek**, Poland
9. SIRT1 OVEREXPRESSION INDUCES PERICYTE RECRUITMENT IN THE RETINA  
**David Ramos**, Spain
10. ECONOMIC EVALUATION STUDIES OF OPHTHALMIC MEDICINES: A SYSTEMATIC REVIEW  
**Inês Ribeiro**, Portugal
11. MOLECULAR ANALYSIS OF BASAL CELL CARCINOMA FOLLOWING VISMODEGIB BIOLOGIC TREATMENT BLOCKING HEDGEHOG PATHWAY  
**Shirel Rossenwasser Weiss**, Israel
12. THE EFFECTS OF IMAGE BRIGHTNESS AND CONTRAST DYNAMIC ALTERING STIMULI (DAS) WHEN VIEWING VIDEO CONTENT ON OCULAR BLOOD FLOW  
**Brent Siesky**, USA
13. EFFICACY AND SAFETY OF LIFITEGRAST OPHTHALMIC SOLUTION 5.0% FOR THE TREATMENT OF DRY EYE DISEASE (DED): COMBINED EVIDENCE FROM FIVE RANDOMIZED CONTROLLED TRIALS  
**Joseph Tauber**, USA
14. SUSTAINED RELEASE SYSTEMS OF FLURBIPROFEN FOR INTRAOCULAR USE  
**Miltiadis K. Tsilimbaris**, Greece

## POSTER PRESENTATIONS (Cont.)

15. ACCELERATED (9 Mw/Cm<sup>2</sup>) CORNEAL COLLAGEN CROSSLINKING FOR PROGRESSIVE KERATOCONUS: TWO-YEAR FOLLOW-UP  
**Omur Ucakhan Gunduz**, Turkey
16. EFFICACY OF TWO DIFFERENT CYCLOSPORIN A FORMULATIONS IN A RABBIT DRY EYE MODEL  
**Omur Ucakhan Gunduz**, Turkey
17. SUTURELESS AMNIOTIC MEMBRANE TRANSPLANTATION IN ACUTE STEVENS-JOHNSON SYNDROME  
**Omur Ucakhan Gunduz**, Turkey
18. TIM2: A NEW PLAYER IN IRON HOMEOSTASIS IN THE RETINA  
**Andreia Valença**, Portugal
19. COMPARISON OF THE CORNEAL AND SCLERAL PENETRATION BETWEEN CYCLODEXTRIN-CONTAINING EYE DROPS AND TobraDex® IN RABBITS EX VIVO  
**Xin Zhao**, China
20. AZITHROMYCIN AS A POSSIBLE NEUROPROTECTIVE DRUG FOLLOWING OPTIC NERVE CRUSH INDUCTION IN MICE  
**Ofira Zloto**, Israel

## COMPANY SPONSORED SESSION

Friday, March 2, 2018



---

12:30-14:00	MODERN PERSPECTIVES ON DRY EYE DISEASE
12:30	THE IMPORTANCE OF INFLAMMATION IN DRY EYE DISEASE <b>Penny A. Asbell, USA</b>
12:40	DEBATE: DO WE HAVE EVIDENCE THAT DRY EYE DISEASE IS PROGRESSIVE? <b>Jay S. Pepose, Joseph Tauber, USA</b>
13:05	DRY EYE DISEASE IN CLINICAL PRACTICE <b>Irit Bahar, Israel</b>
13:10	Q & A
13:15	CLOSE, FOLLOWED BY LUNCH